A Registry Study on HIV-related Lymphoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: AIDS Related Lymphoma, HIV Related Lymphoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Germany, Netherlands, Spain, United Kingdom
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Characteristics, Treatment and Outcomes of HIV-infected Patients With Malignant Lymphoma: A Registry Study of the European Hematology Association (EHA) Lymphoma Group
Overview
Retrospective und prospective registry on HIV-associated lymphoma. Data on characteristics, type and toxicity of treatment and outcome of patients with HIV-lymphoma will be collected.
Detailed description
To study characteristics, treatment approaches and outcome of HIV-infected patients with malignant lymphoma in the combination antiretroviral therapy (cART) era. HIV-infected persons diagnosed with non-Hodgkin lymphoma or Hodgkin lymphoma will be included. The choice of treatment is not specified by the registry study. However, the type of antineoplastic treatment should follow national or international recommendations and guidelines. Data will be pseudonymized by the data manager of the treating institution. Central data management is located at Red Cross Hospital Munich, Germany.
Primary outcome measures
- 2-year overall survival (OS) [Time frame: 2 years]
- 2-year progression-free survival (PFS) [Time frame: 2 years]
Secondary outcome measures (4)
- Incidence of relapse (IR) [Time frame: 5 years]
- Non-relapse mortality (NRM) [Time frame: 5 years]
- 5-year overall survival (OS) [Time frame: 5 years]
- 5-year progression-free survival (PFS) [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- Histology or cytology proven non-Hodgkin lymphoma or Hodgkin lymphoma
- HIV-infection at time of lymphoma diagnosis
- Lymphoma diagnosis since 01.01.2010
- Adult patients ≥ 18 years
- Written informed consent
Exclusion criteria
- HIV-diagnosis > 3 months after the diagnosis of malignant lymphoma
- Non-Compliance or lack of opportunity for follow-up (for the prospective part of the study)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Germany · 2 centers
- Red Cross Hospital Munich — Munich
- University Hospital Cologne — Cologne
Spain · 2 centers
- Hospital de la Santa Creu i Sant Pau — Barcelona
- Hospital Universitario de Salamanca — Salamanca
Netherlands · 1 center
- Amsterdam University Medical Centers — Amsterdam
United Kingdom · 1 center
- University Hospital of Wales — Cardiff
Identifiers
NCT: NCT05231135 · IN03/0121